Last €2.33 EUR
Change Today -0.02 / -0.85%
Volume 0.0
NZW1 On Other Exchanges
As of 12:59 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

threshold pharmaceuticals (NZW1) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - €4.33
52 Week Low
10/13/14 - €2.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

threshold pharmaceuticals (NZW1) Related Businessweek News

No Related Businessweek News Found

threshold pharmaceuticals (NZW1) Details

Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and various earlier-stage clinical trials for therapeutic areas, including advanced leukemias, multiple myeloma, advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Threshold Pharmaceuticals, Inc. has a license and co-development agreement with Merck KGaA to co-develop and commercialize TH-302; and license agreement with Eleison Pharmaceuticals, Inc. for the development and commercialization of glufosfamide for the treatment of cancer in humans and animals. The company was founded in 2001 and is headquartered in South San Francisco, California.

58 Employees
Last Reported Date: 08/1/14
Founded in 2001

threshold pharmaceuticals (NZW1) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $575.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $263.0K
Senior Vice President of Clinical Operations ...
Total Annual Compensation: $418.4K
Senior Vice President of Discovery Research
Total Annual Compensation: $398.4K
Chief Medical Officer
Total Annual Compensation: $361.0K
Compensation as of Fiscal Year 2013.

threshold pharmaceuticals (NZW1) Key Developments

Threshold Pharmaceuticals Seeks Acquisitions

Threshold Pharmaceuticals Inc. (NasdaqCM:THLD) is seeking acquisitions. Threshold Pharmaceuticals said, "Our strategy may include acquiring or in-licensing additional product candidates or development programs that build on our expertise and complement our pipeline. Any growth through acquisition or in-licensing will depend upon the availability of suitable product candidates at favorable prices and upon advantageous terms and conditions. Even if appropriate acquisition or in-licensing opportunities are available, we may not have the financial resources necessary to pursue them. In addition, other companies, many of which may have substantially greater financial, marketing and sales resources, compete with us for acquisition or in-licensing opportunities. In addition, we may not be able to realize the anticipated benefits of any acquisition or in-licensing opportunity for a variety of reasons, including the possibility that a product candidate proves not to be safe or effective in later clinical trials or the integration of an acquired or licensed product candidate gives rise to unforeseen difficulties and expenditures."

Threshold Pharmaceuticals Seeks To Raise Capital

Threshold Pharmaceuticals Inc. (NasdaqCM:THLD) seeks to raise capital through a variety of sources. Threshold Pharmaceuticals said, "We may seek to raise capital through a variety of sources, including the public equity market, including pursuant to our at market issuance sales agreement, or the Sales Agreement, with MLV & Co. LLC, or MLV; private equity financing; collaborative arrangements; licensing arrangements; and/or public or private debt.”

Threshold Pharmaceuticals Announces Phase 3 Trial of TH-302 in Patients with Advanced Soft Tissue Sarcoma

Threshold Pharmaceuticals Inc. announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS). Based on their analyses, which included an assessment of both benefit and risk, the IDMC recommended that the trial should continue as planned to its natural conclusion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NZW1:GR €2.33 EUR -0.02

NZW1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NZW1.
View Industry Companies

Industry Analysis


Industry Average

Valuation NZW1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THRESHOLD PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at